Biomarkers for renal recovery - a translational approach for outcome assessment of critically ill patients with acute kidney injury

Biomarkers for renal recovery - a translational approach for outcome assessment of critically ill patients with acute kidney injury - Renal Recovery

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021444

Enrollment

500

Registered

2020-05-27

Start date

2016-12-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N17

Interventions

Group 1: In critical ill patients with AKI (KDIGO stage 2 or 3), urine and blood samples are collected and biomarkers for renal recovery determined.

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Critically ill patients with KDIGO stage 2 and 3 2. Age 18 – 90 years 3. Informed consent

Exclusion criteria

Exclusion criteria: 1. Previous renal replacement therapy due to AKI in the last 90 days 2. chronic kidney disease with a glomerular filtration rate < 30 ml/min 3. Dialysis-dependent chronic kidney insufficiency 4. Kidney transplant within the last 12 months 5. AKI caused by permanent occlusion or surgical lesion of the renal artery 6. AKI caused by (glomerulo)nephritis, interstitial nephritis, vasculitis 7. Prenancy or nursing period 8. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator

Design outcomes

Primary

Measure	Time frame
Predictive value of biomarkers for renal recovery (short- and long-term).	—

Secondary

Measure	Time frame
• AKI progression (=persistent AKI with a duration of =72h) AND short-term renal recovery (=transient AKI) • Renal recovery at days 90 and 365 • Dialysis dependency at days 90 and 365 • Mortality at days 90 and 365 • MAKE 90, 365 (=Major adverse kidney events: combined endpoint consisting of persistent renal dysfunction, dialysis dependency and mortality at day 90 and 365) • Complications at day 90 and 365 (cerebral insult, cardiovascular diseases, myocardial infarction) • ICU stay and hospital stay	—

Measure

Time frame

• AKI progression (=persistent AKI with a duration of =72h) AND short-term renal recovery (=transient AKI) • Renal recovery at days 90 and 365 • Dialysis dependency at days 90 and 365 • Mortality at days 90 and 365 • MAKE 90, 365 (=Major adverse kidney events: combined endpoint consisting of persistent renal dysfunction, dialysis dependency and mortality at day 90 and 365) • Complications at day 90 and 365 (cerebral insult, cardiovascular diseases, myocardial infarction) • ICU stay and hospital stay

—

Countries

Germany

Contacts

Public ContactMelanie Meersch

Universitätsklinikum Münster Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie

meersch@uni-muenster.de02518347255

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026